Witryna免疫治疗联合贝伐单抗:IMmotion151 研究 IMmotion151研究是一项对比阿替利珠单抗+贝伐珠单抗与舒尼替尼单抗在不适宜手术的局灶性晚期/转移性肾癌中疗效的3期临床试验。 Witryna28 mar 2024 · IMmotion151 (NCT02420821) 是一项多中心、开放、III期、随机对照试验,在先前未经治疗的晚期肾细胞癌患者中进行了阿特珠单抗+贝伐单抗治疗 (n=454) 与舒尼替尼治疗 (n=461) 的对比,共同主要终点是研究人员评估的免疫细胞(IC、PD-L1+)上表达 PD-L1 ≥ 1% 的患者的无进展生存期(PFS)和意向治疗中的总生存期(OS)。 …
Atezolizumab plus bevacizumab versus sunitinib in patients with ...
Witryna20 kwi 2024 · 在近日举行的2024年AACR大会上,IMmotion151研究更新了最终OS结果,并在基因组分类中探索性分析,以期找到指导治疗的标志物。肿瘤瞭望特邀上海交通大学医学院附属仁济医院泌尿科翟炜教授对该研究介绍和点评如下。 研究简介 Witryna1 cze 2024 · Conclusions: PROs in IMmotion151 suggest lower overall treatment burden with atezolizumab plus bevacizumab compared with sunitinib in patients with treatment-naïve mRCC and provide further evidence for clinical benefit of this regimen. ©2024 American Association for Cancer Research. early dawn microfinance company
Cancer Cell 肾癌分子分型关联免疫和靶向药疗效 - 知乎
Witryna1 lut 2024 · Design, setting, and participants: IMmotion151 was a multicenter, open-label, phase 3 randomized clinical trial that compared the efficacy and safety of atezolizumab plus bevacizumab vs sunitinib in patients with untreated mRCC. IMmotion151 included patients from 152 academic medical centers and community … Witryna19 paź 2024 · IMmotion151研究 2024年ASCO-GU会议公布了T药+贝伐珠单抗对比舒尼替尼用于晚期肾癌一线治疗的Ⅲ期临床研究,主要终点为研究者评估的PD-L1表达阳性(IC≥1%)患者PFS及意向治疗人群(ITT)的OS。 结果显示:研究者评估的PD-L1+患者的PFS在联合治疗组显著优于舒尼替尼组(11.2个月vs7.7个月,HR … Witryna1 lip 2024 · IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with ... early dawn crab boat